CytoDyn Inc. Overview

CytoDyn Inc., a biotechnology company operating within the health care sector, is focused on developing innovative therapies for the treatment of human immunodeficiency virus (HIV). The company has a global reach, serving patients worldwide. CytoDyn Inc. is listed on the OTC Bulletin Board, with its financials reported in USD.

Financial Snapshot

As of July 22, 2025, CytoDyn Inc.’s close price stood at $0.29. Over the past year, the company’s stock has experienced significant volatility, with a 52-week high of $0.49 on February 23, 2025, and a 52-week low of $0.10 on December 5, 2024. The company’s market capitalization is currently valued at approximately $389.45 million.

Financial Ratios

The price-to-earnings (P/E) ratio for CytoDyn Inc. is reported at -32.94, indicating that the company is not currently generating profits. This negative P/E ratio is reflective of the company’s ongoing investment in research and development, typical for firms in the biotechnology sector.

Company Focus

CytoDyn Inc. remains dedicated to its mission of advancing HIV treatment options. The company’s efforts are centered on the development of new therapies that could potentially transform the management and treatment of HIV, contributing to global health improvements.